Synonyms: PF-03446962
Ascrinvacumab (Anti-ACVRL1 / ALK-1) is a human IgG2 monoclonal antibody targeting ALK-1. It can be used for the treatment of hepatocellular carcinoma (HCC), in patients with advanced solid tumors. It also demonstrates its use in antiangiogenic therapy. MW : 150 KD.
| Name | Citation | ALK | Others |
|---|---|---|---|
| TAE684 (NVP-TAE684) | 83 | ||
| AP26113-analog (ALK-IN-1) | 4 | EGFR(C797S/del19),IGF1R,EGFR(del19) | |
| GSK1838705A | 18 | Insulin Receptor,IGF-1R | |
| AZD3463 | 7 | IGF-1R | |
| ASP3026 | 4 | ||
| NVL-655 (Neladalkib) | 1 | ROS1,TrkB,FAK | |
| Envonalkib | 0 | ||
| TL13-112 | 0 | ||
| ZX-29 | 0 | ||
| MS4078 | 0 | ||
| Ensartinib dihydrochloride | 7 | TPM3-TRKA,GOPC-ROS1,TRKC | |
| Belizatinib (TSR-011) | 0 | TrkC,TrkB,TrkA | |
| Repotrectinib (TPX-0005) | 12 | Trk receptor,ROS1,Src | |
| APG-2449 | 0 | ||
| Iruplinalkib | 0 | ROS1 | |
| Conteltinib(CT-707) | 0 | Pyk2,FAK | |
| Itacnosertib (TP-0184) | 0 | ||
| Zilurgisertib fumarate | 0 | ||
| ALK inhibitor 1 | 0 | FAK,TSSK2 | |
| X-376 | 0 | ||
| HG-14-10-04 | 0 |
| Description |
Ascrinvacumab (Anti-ACVRL1 / ALK-1) is a human IgG2 monoclonal antibody targeting ALK-1. It can be used for the treatment of hepatocellular carcinoma (HCC), in patients with advanced solid tumors. It also demonstrates its use in antiangiogenic therapy. MW : 150 KD.
|
|---|
| CAS No. | 1463459-96-2 |
|---|---|
| Molecular Weight | 150 kDa |
| Isotype | Human IgG2SA |
| Source | CHO |
| Purification | AKTA |
| Sterility | 0.2 μM filtered |
| Formulation | 100 mM Pro-Ac, 20mM Arg, pH5.0 |
| Storage (From the date of receipt) |
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles. |
*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.